Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites

PURPOSE: Bendamustine is a unique alkylating agent indicated for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B cell non-Hodgkin’s lymphoma. Despite the extensive experience with bendamustine, its pharmacokinetic profile has only recently been described. This over...

Descripción completa

Detalles Bibliográficos
Autores principales: Darwish, Mona, Bond, Mary, Hellriegel, Edward, Robertson, Philmore, Chovan, James P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4441746/
https://www.ncbi.nlm.nih.gov/pubmed/25829094
http://dx.doi.org/10.1007/s00280-015-2727-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4441746/
https://www.ncbi.nlm.nih.gov/pubmed/25829094
http://dx.doi.org/10.1007/s00280-015-2727-6

Ejemplares similares